Zwink, Nadine; Rissmann, Anke; Poetzsch, Simone et al.
Parental risk factors of anorectal malformations: Analysis with a regional population-based control groupBIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY. Bd. 106. H. 2. 2016 S. 133-141
Metayer, Catherine; Petridou, Eleni; Mejia Arangure, Juan Manuel et al.
Parental Tobacco Smoking and Acute Myeloid Leukemia The Childhood Leukemia International ConsortiumAMERICAN JOURNAL OF EPIDEMIOLOGY. Bd. 184. H. 4. 2016 S. 261-273
Urschitz, MS; Gebhard, B; PHilippi, H et al.
Partizipation und Bildung als Endpunkte in der pädiatrischen Versorgungsforschung [Participation and education as outcomes of paediatric health services research]Kinder- und Jugendmedizin. Bd. 16. H. 3. 2016 S. :206-217
Waisman, Ari; Hoevelmeyer, Nadine; Diefenbach, Andreas et al.
Past, present and future of immunology in MainzCELLULAR IMMUNOLOGY. Bd. 308. 2016 S. 1-6
Schmidt, T.; Lorenz, N.; Raker, V. K. et al.
Pathogen recognition receptor-mediated immune processes in low zone tolerance to allergensEXPERIMENTAL DERMATOLOGY. Bd. 25. H. 3. 2016 S. E2-E2
Lackner, K. J.; Mueller-Calleja, N.
Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogmaJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 14. H. 6. 2016 S. 1117-1120
Lackner, K. J.; Mueller-Calleja, N.
Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: replyJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 14. H. 12. 2016 S. 2563-2564
Wittenmeier, Eva; Goeters, Christiane; Becke, Karin
Patient Blood Management Does the Approach also make sense in Children?ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE. Bd. 51. H. 5. 2016 S. 296-306
Distler, Eva; Albrecht, Jana; Brunk, Ariane et al.
Patient-individualized CD8(+) cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient miceINTERNATIONAL JOURNAL OF CANCER. Bd. 138. H. 5. 2016 S. 1256-1268
Hilbert, F.; Gropp-Meier, M.; Schmalfeldt, B. et al.
Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy +/- pertuzumab for platinum-resistant ovarian cancer (PROC)ONCOLOGY RESEARCH AND TREATMENT. Bd. 39. 2016 S. 138-138